James Edgemond - 15 Mar 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: CFO AND TREASURER
Issuer ticker: UTHR
Reported as of: 15 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 17:10:01 UTC
Prior SEC filing: 16 Dec 2025
Next SEC filing: 24 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

James Edgemond filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 17 Mar 2026.

Key facts

This page summarizes James Edgemond's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 17:10.

Change

Previous filing in this sequence was filed on 16 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636178 Primary reporting owner

EDGEMOND JAMES

Relationship: CFO AND TREASURER
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,380
Change %: +127%
Price
Shares after: 18,564
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1, F2

UTHR transaction

Common Stock

Options Exercise

Transaction value
Shares: +9,098
Change %: +49%
Price
Shares after: 27,662
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

UTHR transaction

Common Stock

Tax liability

Transaction value
Shares: -4,682
Change %: -17%
Price: $536.12^*
Shares after: 22,980
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F3

UTHR transaction

Common Stock

Tax liability

Transaction value
Shares: -4,104
Change %: -18%
Price: $536.12^*
Shares after: 18,876
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -10,380
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,380
Exercise price
Footnotes: F1, F4

UTHR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -9,098
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,098
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F2

Includes 42 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.

Footnote F3

Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

Footnote F4

Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.